India opens vaccination for children, booster shots for frontline workers

Citizens above the age of 60 years with comorbidites will be given shots from Jan 10, after consultation with the doctors

Narendra Modi
Prime Minister Narendra Modi
Sohini Das Mumbai
2 min read Last Updated : Dec 25 2021 | 11:00 PM IST
Amid fears of the Omicron variant virus spreading rapidly across the country, Prime Minister Narendra Modi announced that vaccinations for children aged between 15-18, and precautionary shots for the elderly will be opened up from New Year.

India has 415 Omicron cases as of today.

In an address to the nation, PM Modi said that children between 15 and 18 years will be vaccinated from January 3, 2022. He added that precautionary doses of vaccines will be given to healthcare and frontline workers from January 10, 2022. Also, citizens above the age of 60 years with comorbidites will be given shots from Jan 10, after consultation with the doctors.

PM Modi said as people prepare to welcome the New Year, it's also a time to be careful as the highly contagious Omicron variant is rapidly pushing up Covid infections across the world and in India as well.

As for children, Cadila Healthcare’s DNA vaccine has been approved for 12 year old and above.

Earlier in the day, Bharat Biotech’s Covaxin was approved by the country’s drug regulator for use in children between 12 and 18 years. The company noted that the vaccine has been formulated in such a way that the same dosage can be administered to adults and children.

On October 12, the Subject Expert Committee (SEC) that advises the Drugs Controller General of India (DCGI) had approved the use of Covaxin in children as young as two years and above.

The firm was asked to submit data on any adverse event following vaccination every 15-days for the next two months. The SEC had asked Bharat Biotech to continue the study according to the whole virion, inactivated coronavirus vaccine-approved clinical trial protocol.

Moreover, the firm was asked to submit safety data, including data on adverse events following immunisation (AEFI) and Adverse event of special interest (AESI) every 15-days for the first two months, and thereafter on a monthly basis.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusOmicronDelta variant of coronavirusNarendra ModihealthcareCoronavirus VaccineCoronavirus Testsdoctorssenior citizens

Next Story